find.bio

Reverse engineering biology

What we do

Find.Bio is a platform for reverse engineering biology.

Our goal is to industrialise early-stage drug discovery: what we call “High Throughput Discovery”





How we do it

Our approach is rooted in the mapping of *interactomes*: the set of all possible interactions among collections of small molecules and proteins of interest.

The ability to create such maps for complete *proteomes* (ie for all the proteins in an organism) opens a range of discovery opportunities, notably scalable target discovery and drug repurposing.

LEARN MORE ABOUT STRUCTURAL BIOLOGY

How it works

The heart of our platform is a structure-based, AI-powered screening engine, running on 500K CPU cores - built from the ground up for interactome mapping.



Who we are

Our team has deep experience in drug-design, machine learning, molecular modelling, pharmacology, high-throughput computing, and collaboration.

Who we are

Matt Blumberg
CEO, Founder

Matthew Blumberg (CEO) has been working in the fields of network computing and large scale collaboration for 20 years. Through projects like GridRepublic, Charity Engine, Progress Thru Processors, and others, he has aggregated resources from, and run scientific and commercial applications on, as many as one million CPUs at a time. Matthew is also chairman of the Project Management Committee of the BOINC project (Berkeley Open Infrastructure for Network Computing), and recently completed a year as Visiting Fellow at the Laboratory for Innovation Science at Harvard.

Aurélien Grosdidier
CSO, PharmD, PhD

Aurelien Grosdidier, PharmD, PhD (CSO), while at the Swiss Institute of Bioinformatics (SIB), was responsible for the design, development and maintenance of drug-design tools such as the application EADock and the website SwissDock, the first online molecular docking solution for drug-design based on a universal physical description of proteins and ligands, combined with a hybrid machine learning engine. He also made decisive scientific and technical contributions to the suite of structural biology / drug-design tools provided by the SIB: SwissParam, SwissBioisostere, SwissSideChain, SwissTargetPrediction, SwissADME, SwissSimilarities, and Click2Drug.

Who we are

Tristan Olive
Co-CTO, System Architect

Rytis Slatkevičius
Co-CTO, Operations

Tristan Olive & Rytis Slatkevičius (Co-CTOs) are the technical team behind Charity Engine, GridRepublic, Progress Thru Processors, PrimeGrid, and other global distributed computing projects. They bring to Find.Bio decades each of experience in high-throughput scientific computing, development and management of platforms and infrastructure on a global scale, and design of human interfaces.

Duygu Yilmazer
PhD, Researcher

Natasha Seelam
PhD candidate, Researcher

Duygu Yilmazer, PhD PostDoc & Visiting Researcher, University of Gothenburg, Department of Chemistry and Molecular Biology.

Natasha Seelam, PhD candidate, Chemical Engineering, MIT.

Find.Bio
Cambridge, Massachusetts
United States

CONTACT US